Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis
Pitt M, Crathorne L, Moxham T, Bond M, Hyde C

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
The purpose of the ERG report was to comment on the validity of the manufacturer’s submission on the technology of interest. The scope for this submission and hence the scope for the ERG report is shown in Table 1.

Authors' conclusions
The ERG was generally in agreement with the submitting manufacturer concerning its estimates of effectiveness. There was greater concern about the estimates of cost-effectiveness. The ERG judged that if the potential errors were corrected, the ICERs offered by the submitting manufacturer overstate the cost-effectiveness of everolimus for the second-line treatment of metastatic RCC (this ICER would be higher).

Project page URL
http://www.hta.ac.uk/erg/supplements/supplement1402.pdf#nameddest=article06

Final publication URL
http://www.hta.ac.uk/project/2155.asp

PubMedID
21047490

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Agents /economics /therapeutic use; Carcinoma, Renal Cell /drug therapy /economics /pathology; Cost-Benefit Analysis; England; Everolimus; Kidney Neoplasms /drug therapy /economics /pathology; Randomized Controlled Trials as Topic; Sirolimus /analogs & derivatives /economics /therapeutic use; Wales

Language Published
English

Country of organisation
England

Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

AccessionNumber
32011000931
Date abstract record published
22/06/2011